Precision Learning for Confident Primary Biliary Cholangitis (PBC) Care

Target Audience

This educational series will address identified knowledge and practice gaps among gastroenterologists, hepatologists, and specialist nurse practitioners (NPs) and physician associates (PAs) related to the management of primary biliary cholangitis (PBC)—and among primary care and internal medicine clinicians related to early identification and referral of patients with suspected PBC.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the clinical presentation of PBC, prompting timely workup, diagnosis, and first-line treatment initiation
• Apply the latest evidence, individual patient profiles, and monitoring thresholds to treatment escalation decisions, including selection of second-line therapies
• Integrate patient-centered considerations, particularly symptoms and quality-of-life burdens, to both pharmacologic and nonpharmacologic management decisions

Program Overview

Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease that can lead to liver failure and the need for liver transplantation if left untreated. Despite advances in diagnostic tools and novel therapies, PBC remains frequently underdiagnosed or misdiagnosed. This Test & Teach™ program is the first in an educational series designed to address key aspects of PBC management. In this introductory activity, learners will review foundational concepts related to PBC diagnosis, pathophysiology, and treatment. Using a confidence-based self-assessment format, the activity will help clinicians evaluate their current knowledge and identify areas of uncertainty to guide more-targeted learning throughout the series. Collectively, the series will address PBC identification, diagnosis, treatment, monitoring, and comprehensive patient care, with the overarching goal of improving clinician knowledge and evidence-based practice to enhance patient outcomes.

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pretest, pass the posttest with a 70% score or higher, and submit an evaluation form.

Fee Information

There is no fee for this activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Nancy S. Reau, MD

Consulting Fees: Arbutus Biopharma, Bluejay, Gilead Sciences, Inc., Salix Pharmaceuticals, Inc., Vir Biotechnology, Inc.

Contracted Research: AbbVie Inc., Gilead Sciences, Inc. Salix Pharmaceuticals, Inc., Vir Biotechnology, Inc.

The Integritas planners and managers have reported no relevant financial relationships with ineligible companies:

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information 

For information about this activity, please contact us at info@exchangecme.com